Symbiotec Pharmalab Q1 FY27 earnings call

What moved the numbers, as management explained it

• API volume growth and regulated-market mix shift lifted API revenue to ₹215 cr (+6% YoY) and API EBITDA to ₹66 cr (+9% YoY) with gross margins above 60%.
• New-business operating expense drag of INR 23 cr plus depreciation INR 11 cr depressed consolidated EBITDA (INR 45 cr) and PAT (INR 14 cr); new businesses had no revenue in the quarter. (one-off)
• Prior-period base effect: Q1 FY26 pre-operative expenses of new businesses were capitalised rather than expensed, making the YoY comparison not like-for-like. (accounting)
• Backward-integrated 'make vs buy' model protected API gross margins despite global solvent and logistics cost uncertainties cited by management.

The numbers management led with

• New-business operating expense drag: INR 23 crores per quarter run-rate for next 2–3 quarters
• Forward annual capex guidance: INR 200–250 crores per year for next 2–3 years
• Phase 1 fermentation capacity expansion: 600 kL brownfield; 15–18 month execution; construction to start Q3 FY27

The company's filed results for this quarter are not on file with us yet; these are management's own figures from the call.

Guidance on this call

By business

Balance sheet, capex and funding

• Net debt as of 30 June 2026: INR 398 cr
• IPO proceeds net of expenses: INR 142 cr
• Net debt currently ~INR 326 cr after IPO proceeds and Q2 capex outflows
• Q1 FY27 capex: INR 68 cr
• Planned capex: INR 200-250 cr per year for next 2-3 years
• Phase 1 600 kL fermentation brownfield expansion 15-18 months; construction to start Q3 FY27; partly funded by customer capital (skin in the game)

The industry, as management sees it

Management framed biomanufacturing/synthetic biology as a multi-billion-dollar TAM opportunity, citing McKinsey/BCG estimates that over a billion litres of fermentation capacity will be needed over the next decade versus only a few million litres currently — implying significant runway for low-cost, FDA-audited fermentation CDMOs like Symbiotec. For complex injectables, the DCV ready-to-use/ready-to-dispense format is positioned as a value-additive shift from traditional single-vial systems.

Risks management named

• Lumpiness in first half of FY27 because opex/depreciation from new businesses flows through P&L while milestone revenues arrive in H2
• Global operating environment uncertainties (solvents, shipping costs) that API business cannot fully hedge as it is not backward-integrated on solvents
• Timing risk on Premarin generic launch — API development complete but depends on partner's formulation development and FDA approval

Not answered directly

• DCV milestone payment quantum
• FY29 sales mix between API and new verticals
• Specific contract-level revenue figures under take-or-pay agreements

Asked for a number, answered without one

• Take-or-pay contract minimum revenue and upside: Cannot drive into specifics of each contract; only that each is a multi-million-dollar opportunity at Phase 0 (existing 400 kL) capacity; further details restricted by customer confidentiality.
• Revenue per litre of fermentation benchmark: Cannot share specifics of contract numbers or capacities blocked for each customer; said only that asset-turn ratios should be greater than 1 for biomanufacturing.
• DCV milestone payment quantum and frequency: Confidentiality prevents specific numbers; said all milestone cash flows in H2 will set off FY27 opex drag; characterised as substantial multi-million dollars.
• Premarin generic launch timing: Symbiotec API development done but formulation is partner-controlled; said cannot give guidance on Premarin generic launch timing.

Every question, with its answer

1. 1. Biotech CDMO capacity and revenue outlook

   Saion Mukherjee, Nomura Holdings26:11

   Question. On the fermentation business, what is the 5-year visibility on capacity and revenue? How many such contracts can we expect over 5 years given capacity and execution constraints? How do the take-or-pay contracts work — what's the minimum value and upside?

   Answer, Anil Satwani, Chairman and Managing Director. Today Symbiotec has ~400 kL of fermentation capacity, of which a large part is already booked through Phase 0 contracts/term sheets. Existing two customers alone require ~4x current capacity — Phase 1 in 2–3 years, then Phase 2. He is also in advanced discussion with half a dozen other potential customers each needing a million litres. Take-or-pay contracts guarantee minimum revenue even if customer demand falls short; on confidentiality he declined to disclose specific numbers but said each contract is a multi-million-dollar opportunity from Phase 0 alone.

   Follow-up. Any benchmark of revenue per litre of fermentation, and what minimum revenue can we lock in from take-or-pay contracts?

   Answer. Anil Satwani said he cannot share specific contract numbers due to confidentiality, but gave asset-turnover guidance >1x and described each contract as multi-million-dollar. Revenues from biotech CDMO expected to start in Q4 FY27 with a significant chunk in next fiscal.

   Partly answered.

2. 2. API growth and margin sustainability

   Saion Mukherjee, Nomura Holdings33:37

   Question. On the API business, what is the sustainability of the 7% YoY revenue growth and 60%+ gross margin? Any cyclicity at play?

   Answer, Anil Satwani, Chairman and Managing Director. Said API business is 'rock solid' given global position in DMFs/CEP qualifications; sticky customer base; backward integration on intermediates provides a make-vs-buy flexibility to protect margins. Mix shift toward regulated markets and higher-value products is driving margin expansion; expects gross margin ~60% and EBITDA margin ~30% to be maintained, with some quarter-to-quarter variation from solvents and shipping where the company is not backward-integrated.

3. 3. DCV product pipeline

   Tushar Manudhane, Motilal Oswal Financial Services37:02

   Question. On DCV, beyond the two products already disclosed, how many more will be filed over the next 12–24 months?

   Answer, Anil Satwani, Chairman and Managing Director. 5–6 DCV products have already been developed and are going into plant-level validation in the coming quarters. Capacity is the constraint, not products; depending on partner offtake estimates, a second line may be needed soon — a 'good problem to have'. Approvals expected in FY28, allowing validation of remaining products.

4. 4. Phase 1 capacity expansion

   Tushar Manudhane, Motilal Oswal Financial Services39:13

   Question. Is the 600 kL new biotech capacity for an existing customer or a new customer?

   Answer, Anil Satwani, Chairman and Managing Director. 400 kL is largely booked by existing contracts (Phase 0). The 600 kL Phase 1 is for an existing customer with whom a term sheet has been signed; construction to start in Q3 FY27 with a 15–18 month execution window, leveraging existing 400 kL in the interim.

   Follow-up. What is the overall capex for the next two years on top of the INR 1,000 cr already committed?

   Answer. Said capex is a function of customer contracts; based on current visibility expects INR 200–250 cr per annum for next 2–3 years, funded from internal accruals; further upside if more contracts materialise.

5. 5. New-business expense run-rate

   Harith Ahamed, Avendus Spark55:03

   Question. The INR 23 cr new-business opex drag — should we expect this run-rate for the rest of FY27, or a step-up closer to commercial supplies?

   Answer, Raghavender Ramachandran, Chief Financial Officer. INR 23 cr of opex run-rate should more or less continue for the next two to three quarters, similarly INR 11 cr of depreciation, subject to small inflationary increase. Q1 was a good representative run-rate.

6. 6. Milestone payments and revenue profile of new verticals

   Harith Ahamed, Avendus Spark55:25

   Question. What triggers the H2 milestones, ballpark size, and any insulin or non-US DCV revenues expected in FY27?

   Answer, Anil Satwani, Chairman and Managing Director. Cannot share exact numbers due to customer confidentiality, but H2 milestone revenues from both subsidiaries will fully offset the opex drag for FY27 (Q3 and Q4). Insulin/biologics commercial revenues will only kick in early next fiscal year — plant is ready but DCGI approval and stability studies still pending; working as a CMO so no clinical trials required.

   Not answered directly.

7. 7. API capex and revenue

   Sagar Tanna, Alchemie Ventures56:13

   Question. How much capex has been incurred on the API business and when will it generate commercial revenues?

   Answer, Raghavender Ramachandran, Chief Financial Officer. API gross block as of 30 June is ~INR 640 cr, generating INR 800–900 cr of revenue today. API business is already commercial; only new businesses (CDMO + injectables) have revenue starting in 6–12 months.

8. 8. API capacity utilisation

   Sagar Tanna, Alchemie Ventures56:19

   Question. What is the current capacity utilisation on the API business?

   Answer, Raghavender Ramachandran, Chief Financial Officer. Roughly 70%–80%.

9. 9. Guidance scope and PAT outlook

   Anubhav Sahu, McPro Research56:34

   Question. The 20% revenue / 25% EBITDA guidance — is it consol-level? Any colour on net profit trajectory?

   Answer, Raghavender Ramachandran, Chief Financial Officer. Yes, the guidance is at consolidated level. Net profit growth will be slightly lower than EBITDA growth because of incremental depreciation drag; cash PAT growth should still be >25%.

10. 10. Phase 1 capex and funding

    Anubhav Sahu, McPro Research56:34

    Question. What is the capex outlay for the 600 kL expansion, and is it for one of the three existing customers?

    Answer, Anil Satwani, Chairman and Managing Director. 600 kL Phase 1 is for a customer with whom a term sheet has been signed. To be funded by a combination of internal accruals and customer capital — customers put 'skin in the game' because the facility is built exclusively for them. Existing capacities are the 'bait' to onboard customers while Phase 1 is built.

    Follow-up. Does the customer capital participation also involve revenue/profit sharing?

    Answer. No profit-sharing — this is a CMO (time-and-material) arrangement under take-or-pay contracts where the customer pays for use of the facility even if they don't utilise it. No revenue/profit sharing.

11. 11. DCV milestone payments

    Anubhav Sahu, McPro Research56:34

    Question. Any colour on DCV milestone payments — frequency and quantum over the next couple of years?

    Answer, Anil Satwani, Chairman and Managing Director. Cannot share specifics due to customer confidentiality but the milestone quantum is 'substantial' — a multi-million-dollar arrangement that will fully offset the FY27 new-business opex. Math left to the analyst.

    Not answered directly.

12. 12. Prior-period CDMO/injectable revenues

    Kartick Bane, Bajaj Life58:04

    Question. Were there any revenues from the complex injectables/CDMO segments in the prior year? Why no revenue recognised this quarter?

    Answer, Raghavender Ramachandran, Chief Financial Officer. FY26 had ~INR 33 cr of milestone revenue from these segments, recognised in Q4 FY26. Q1 FY27 had no CDMO/injectable revenue — these milestones are lumpy and not quarterly in nature.

    Follow-up. Guidance on R&D as % of sales?

    Answer. CFO said R&D has consistently been 3%–4% of sales; expected to drift up to ~5% in the future.

13. 13. Premarin generic launch timing

    Raaj, Arjav Partners58:38

    Question. When do you expect the launch of the generic version of Premarin in the API division?

    Answer, Anil Satwani, Chairman and Managing Director. Symbiotec has completed its API development, but the formulation development belongs to the partner and is dependent on FDA approval. Cannot give a timing guidance — outside Symbiotec's control.

    Follow-up. What will be the sales mix in FY29 — how much from API vs new businesses?

    Answer. API is currently >90% of revenue, growing at high single digits. Mix will gradually shift; over a 5–6 year horizon, API could be less than half of revenue as DCV and CDMO ramp. Asker wanted FY29 specifics, but Anil declined to give a specific FY29 split.

    Not answered directly.

14. 14. Steady-state margins of new businesses

    Rohan Kampani, JM Financial59:31

    Question. What gross margins and steady-state EBITDA margins should we expect from the CDMO and injectables businesses once at mature utilisation?

    Answer, Anil Satwani, Chairman and Managing Director. Symbiotec does not give forward-looking margin guidance, but the industry trend for complex CMO/CDMO and complex injectables is gross margins >70% and EBITDA margins >35%. Symbiotec's differentiated fermentation biotech CMO and DCV platform should sit in a similar margin range.

    Partly answered.

Topic by topic, in the order it was spoken

In their words